Rose SL. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness. J Law Med Ethics 2013;41:680–687.
McCoy MS, Carniol M, Chockley K, . Conflicts of interest for patient-advocacy organizations. N Engl J Med 2017;376:880–885.
Abola MV, Prasad V. Industry funding of cancer patient advocacy organizations. Mayo Clin Proc 2016;91:1668–1670.
Rothman SM, Raveis VH, Friedman A, . Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices. Am J Public Health 2011;101:602–609.
Clemence M, Gilby N, Shah J, . Wellcome Trust Monitor Wave 2: tracking public views on science, biomedical research and science education. London, UK: Wellcome Trust; May 2013. Available at: https://wellcome.ac.uk/sites/default/files/monitor-wave2-full-wellcome-may13.pdf. Accessed June 20, 2019.
Shah KK, Sussex J, Hernandez-Villafuerte K. Government and charity funding of cancer research: public preferences and choices. Health Res Policy Syst 2015;13:38.
Arias E. United States Life Tables, 2011. Natl Vital Stat Rep 2015;64:1–63.
Fattovich G, Stroffolini T, Zagni I, . Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(Suppl):S35–50.
Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol 2014;109:822–827.
Freedman ND, Abnet CC, Caporaso NE, . Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol 2016;45:846–856.
Harvey JA, Strahilevitz MA. The power of pink: cause-related marketing and the impact on breast cancer. J Am Coll Radiol 2009;6:26–32.
Carter AJ, Nguyen CN. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 2012;12:526.
Burnet NG, Jefferies SJ, Benson RJ, . Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 2005;92:241–245.
Carter AJ, Delarosa B, Hur H. An analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States values. Health Res Policy Syst 2015;13:62.